Market Cap 12.66M
Revenue (ttm) 12.10M
Net Income (ttm) -3.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -29.83%
Debt to Equity Ratio 0.00
Volume 61,285
Avg Vol 376,264
Day's Range N/A - N/A
Shares Out 9.11M
Stochastic %K 11%
Beta 0.65
Analysts Strong Sell
Price Target $7.27

Company Profile

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-...

Industry: Medical Devices
Sector: Healthcare
Phone: 952 426 1383
Website: nmtc1.com
Address:
7599 Anagram Drive, Eden Prairie, United States
You_Juanna_Trade
You_Juanna_Trade Sep. 21 at 6:04 PM
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 18 at 2:27 PM
$NMTC Our new Southern California distribution agreement for the OneRF® Trigeminal Nerve Ablation System builds on our initial commercialization efforts and supports our broader strategy to develop a distribution network across key U.S. markets. Southern California represents an important market for the OneRF® Trigeminal Nerve Ablation System, and this agreement expands commercial access across key counties, including the Los Angeles metropolitan area. As we move forward, we expect to continue evaluating additional distribution relationships to broaden access to the system in other important U.S. markets. $GMED $BSX
0 · Reply
IncognitoBull
IncognitoBull Sep. 17 at 2:25 PM
0 · Reply
IncognitoBull
IncognitoBull Sep. 17 at 1:44 PM
$NMTC $GMED $BSX it's called an Easter Egg....hints....tagged Boston Scientific and Globus Medical....who are we in talks with? Top tier
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 17 at 1:32 PM
$NMTC We are expanding the U.S. commercialization of our FDA-cleared OneRF® Trigeminal Nerve Ablation System through a new distribution agreement covering key Southern California counties, including the Los Angeles metropolitan area. This agreement marks another step in broadening commercial access to OneRF® and expanding our presence across important U.S. markets. As we continue our commercialization efforts, we remain focused on bringing our technology to more physicians and expanding access for patients suffering from trigeminal neuralgia. $GMED $BSX
1 · Reply
MingChoo
MingChoo Sep. 17 at 2:01 AM
$NMTC 53.8% gross margin in Q2…
0 · Reply
Wisenheimer
Wisenheimer Sep. 16 at 7:52 PM
$NMTC advanced discussions for over a year now??? How long has it been this was in a March letter
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 16 at 4:56 PM
$NMTC Our basivertebral nerve ablation program reflects our strategy of applying NeuroOne’s established technology and experience to additional therapeutic areas. We have completed the program’s regulatory strategy, with the system currently expected to follow a 510(k) pathway. Device optimization remains underway, including work to optimize lesion size. We are also engaged in advanced discussions with a potential tier-one strategic partner to develop and supply the access tools for the system as we continue evaluating this opportunity in chronic vertebrogenic lower back pain. $BSX $GMED
1 · Reply
annomymous
annomymous Sep. 16 at 2:07 PM
$NMTC what are you doing NueroOne?! Burned up 95% of shareholder value while your ceo continues to say we’re almost to commercialization. Get creative. Work harder and maybe give up your salary until you stop burning so much cash you have to dilute continuously. Even your new biz dev guy is dumping shares. Shows a lot of optimism. End rant. Wish I never came across this turd
2 · Reply
Wisenheimer
Wisenheimer Sep. 16 at 5:36 AM
$NMTC new biz dev guy already sold shares at $2
1 · Reply
Latest News on NMTC
NeuroOne Medical Technologies Slides: Corporate presentation

Sep 9, 2026, 7:00 AM EDT - 12 days ago

NeuroOne Medical Technologies Slides: Corporate presentation


NeuroOne Medical price target lowered to $5 from $13 at Maxim

2026-08-16T13:20:26.000Z - 5 weeks ago

NeuroOne Medical price target lowered to $5 from $13 at Maxim


NeuroOne Medical Technologies Earnings Call Transcript: Q3 2026

Aug 13, 2026, 8:30 AM EDT - 5 weeks ago

NeuroOne Medical Technologies Earnings Call Transcript: Q3 2026


NeuroOne Medical Technologies Earnings release: Q3 2026

Aug 13, 2026, 8:30 AM EDT - 5 weeks ago

NeuroOne Medical Technologies Earnings release: Q3 2026


NeuroOne Medical Technologies Quarterly report: Q3 2026

Aug 13, 2026, 8:30 AM EDT - 5 weeks ago

NeuroOne Medical Technologies Quarterly report: Q3 2026


NeuroOne Medical Technologies Slides: Corporate presentation

Jun 12, 2026, 7:00 AM EDT - 3 months ago

NeuroOne Medical Technologies Slides: Corporate presentation


NeuroOne Medical target adjusted to $8 from $1.60 at Ladenburg

2026-05-13T12:05:31.000Z - 4 months ago

NeuroOne Medical target adjusted to $8 from $1.60 at Ladenburg


NeuroOne Medical Technologies Earnings Call Transcript: Q2 2026

May 12, 2026, 8:30 AM EDT - 4 months ago

NeuroOne Medical Technologies Earnings Call Transcript: Q2 2026


NeuroOne Medical Technologies Earnings release: Q2 2026

May 12, 2026, 8:30 AM EDT - 4 months ago

NeuroOne Medical Technologies Earnings release: Q2 2026


NeuroOne Medical Technologies Quarterly report: Q2 2026

May 12, 2026, 8:30 AM EDT - 4 months ago

NeuroOne Medical Technologies Quarterly report: Q2 2026


NeuroOne Medical Technologies trading halted, news pending

2026-04-15T23:50:16.000Z - 5 months ago

NeuroOne Medical Technologies trading halted, news pending


NeuroOne Medical Technologies Transcript: Investor update

Mar 12, 2026, 11:30 AM EDT - 6 months ago

NeuroOne Medical Technologies Transcript: Investor update


NeuroOne Medical Technologies Slides: Corporate presentation

Mar 11, 2026, 8:00 AM EDT - 6 months ago

NeuroOne Medical Technologies Slides: Corporate presentation


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 6 months ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical initiated with a Buy at JonesResearch

2026-03-02T12:24:18.000Z - 6 months ago

NeuroOne Medical initiated with a Buy at JonesResearch


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Feb 27, 2026, 7:00 AM EST - 6 months ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical Technologies Earnings Call Transcript: Q1 2026

Feb 17, 2026, 8:30 AM EST - 7 months ago

NeuroOne Medical Technologies Earnings Call Transcript: Q1 2026


NeuroOne Medical Technologies Earnings release: Q1 2026

Feb 17, 2026, 8:30 AM EST - 7 months ago

NeuroOne Medical Technologies Earnings release: Q1 2026


NeuroOne Medical Technologies Quarterly report: Q1 2026

Feb 17, 2026, 8:30 AM EST - 7 months ago

NeuroOne Medical Technologies Quarterly report: Q1 2026


NeuroOne Medical Technologies Slides: Corporate presentation

Dec 22, 2025, 6:00 AM EST - 9 months ago

NeuroOne Medical Technologies Slides: Corporate presentation


NeuroOne Medical Technologies Earnings Call Transcript: Q4 2025

Dec 17, 2025, 8:30 AM EST - 9 months ago

NeuroOne Medical Technologies Earnings Call Transcript: Q4 2025


NeuroOne Medical Technologies Earnings release: Q4 2025

Dec 17, 2025, 8:30 AM EST - 9 months ago

NeuroOne Medical Technologies Earnings release: Q4 2025


NeuroOne Medical Technologies Annual report: Q4 2025

Dec 17, 2025, 8:30 AM EST - 9 months ago

NeuroOne Medical Technologies Annual report: Q4 2025


NeuroOne Medical Technologies Transcript: Investor Update

Oct 7, 2025, 8:30 AM EDT - 11 months ago

NeuroOne Medical Technologies Transcript: Investor Update


NeuroOne Medical initiated with a Buy at Maxim

2025-09-09T11:50:39.000Z - 1 year ago

NeuroOne Medical initiated with a Buy at Maxim


NeuroOne Medical receives FDA 510k clearance for OneRF

2025-08-18T12:35:36.000Z - 1 year ago

NeuroOne Medical receives FDA 510k clearance for OneRF


NeuroOne Medical Technologies Quarterly report: Q3 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

NeuroOne Medical Technologies Quarterly report: Q3 2025


NeuroOne Medical Technologies Earnings release: Q3 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

NeuroOne Medical Technologies Earnings release: Q3 2025


NeuroOne Medical Technologies Quarterly report: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

NeuroOne Medical Technologies Quarterly report: Q2 2025


NeuroOne Medical Technologies Earnings release: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

NeuroOne Medical Technologies Earnings release: Q2 2025


NeuroOne Medical Technologies Slides: Corporate Presentation

May 12, 2025, 7:00 AM EDT - 1 year ago

NeuroOne Medical Technologies Slides: Corporate Presentation


NeuroOne® Issues Letter to Shareholders

Apr 16, 2025, 9:00 AM EDT - 1 year ago

NeuroOne® Issues Letter to Shareholders


NeuroOne Medical Technologies Quarterly report: Q1 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

NeuroOne Medical Technologies Quarterly report: Q1 2025


NeuroOne Medical Technologies Earnings release: Q1 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

NeuroOne Medical Technologies Earnings release: Q1 2025


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Feb 7, 2025, 7:00 AM EST - 1 year ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Feb 5, 2025, 7:00 AM EST - 1 year ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Jan 13, 2025, 7:00 AM EST - 1 year ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical Technologies Transcript: Status Update

Jan 10, 2025, 11:00 AM EST - 1 year ago

NeuroOne Medical Technologies Transcript: Status Update


NeuroOne Medical Technologies Slides: Status Update

Jan 10, 2025, 11:00 AM EST - 1 year ago

NeuroOne Medical Technologies Slides: Status Update


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Jan 10, 2025, 7:00 AM EST - 1 year ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical Technologies Annual report: Q4 2024

Dec 17, 2024, 9:00 AM EST - 1 year ago

NeuroOne Medical Technologies Annual report: Q4 2024


NeuroOne Medical Technologies Earnings Call Transcript: Q3 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

NeuroOne Medical Technologies Earnings Call Transcript: Q3 2024


NeuroOne Medical Technologies Quarterly report: Q3 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

NeuroOne Medical Technologies Quarterly report: Q3 2024


NeuroOne Medical Technologies Earnings release: Q3 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

NeuroOne Medical Technologies Earnings release: Q3 2024


NeuroOne Medical Technologies Earnings Call Transcript: Q2 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

NeuroOne Medical Technologies Earnings Call Transcript: Q2 2024


NeuroOne Medical Technologies Quarterly report: Q2 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

NeuroOne Medical Technologies Quarterly report: Q2 2024


NeuroOne Medical Technologies Earnings release: Q2 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

NeuroOne Medical Technologies Earnings release: Q2 2024


NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology

Apr 10, 2024, 9:00 AM EDT - 2 years ago

NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology


NeuroOne® to Participate in the 36th Annual Roth Conference

Mar 8, 2024, 12:00 PM EST - 2 years ago

NeuroOne® to Participate in the 36th Annual Roth Conference


NeuroOne Medical Technologies Earnings Call Transcript: Q1 2024

Feb 13, 2024, 4:30 PM EST - 2 years ago

NeuroOne Medical Technologies Earnings Call Transcript: Q1 2024


NeuroOne Medical Technologies Quarterly report: Q1 2024

Feb 13, 2024, 4:30 PM EST - 2 years ago

NeuroOne Medical Technologies Quarterly report: Q1 2024


NeuroOne Medical Technologies Earnings release: Q1 2024

Feb 13, 2024, 4:30 PM EST - 2 years ago

NeuroOne Medical Technologies Earnings release: Q1 2024


NeuroOne Medical Technologies Proxy statement: Proxy Filing

Jan 29, 2024, 7:00 AM EST - 2 years ago

NeuroOne Medical Technologies Proxy statement: Proxy Filing


NeuroOne Medical Technologies Earnings Call Transcript: Q4 2023

Dec 14, 2023, 5:00 PM EST - 2 years ago

NeuroOne Medical Technologies Earnings Call Transcript: Q4 2023


NeuroOne Medical Technologies Annual report: Q4 2023

Dec 14, 2023, 5:00 PM EST - 2 years ago

NeuroOne Medical Technologies Annual report: Q4 2023


NeuroOne Medical Technologies Earnings release: Q4 2023

Dec 14, 2023, 5:00 PM EST - 2 years ago

NeuroOne Medical Technologies Earnings release: Q4 2023


You_Juanna_Trade
You_Juanna_Trade Sep. 21 at 6:04 PM
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 18 at 2:27 PM
$NMTC Our new Southern California distribution agreement for the OneRF® Trigeminal Nerve Ablation System builds on our initial commercialization efforts and supports our broader strategy to develop a distribution network across key U.S. markets. Southern California represents an important market for the OneRF® Trigeminal Nerve Ablation System, and this agreement expands commercial access across key counties, including the Los Angeles metropolitan area. As we move forward, we expect to continue evaluating additional distribution relationships to broaden access to the system in other important U.S. markets. $GMED $BSX
0 · Reply
IncognitoBull
IncognitoBull Sep. 17 at 2:25 PM
0 · Reply
IncognitoBull
IncognitoBull Sep. 17 at 1:44 PM
$NMTC $GMED $BSX it's called an Easter Egg....hints....tagged Boston Scientific and Globus Medical....who are we in talks with? Top tier
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 17 at 1:32 PM
$NMTC We are expanding the U.S. commercialization of our FDA-cleared OneRF® Trigeminal Nerve Ablation System through a new distribution agreement covering key Southern California counties, including the Los Angeles metropolitan area. This agreement marks another step in broadening commercial access to OneRF® and expanding our presence across important U.S. markets. As we continue our commercialization efforts, we remain focused on bringing our technology to more physicians and expanding access for patients suffering from trigeminal neuralgia. $GMED $BSX
1 · Reply
MingChoo
MingChoo Sep. 17 at 2:01 AM
$NMTC 53.8% gross margin in Q2…
0 · Reply
Wisenheimer
Wisenheimer Sep. 16 at 7:52 PM
$NMTC advanced discussions for over a year now??? How long has it been this was in a March letter
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 16 at 4:56 PM
$NMTC Our basivertebral nerve ablation program reflects our strategy of applying NeuroOne’s established technology and experience to additional therapeutic areas. We have completed the program’s regulatory strategy, with the system currently expected to follow a 510(k) pathway. Device optimization remains underway, including work to optimize lesion size. We are also engaged in advanced discussions with a potential tier-one strategic partner to develop and supply the access tools for the system as we continue evaluating this opportunity in chronic vertebrogenic lower back pain. $BSX $GMED
1 · Reply
annomymous
annomymous Sep. 16 at 2:07 PM
$NMTC what are you doing NueroOne?! Burned up 95% of shareholder value while your ceo continues to say we’re almost to commercialization. Get creative. Work harder and maybe give up your salary until you stop burning so much cash you have to dilute continuously. Even your new biz dev guy is dumping shares. Shows a lot of optimism. End rant. Wish I never came across this turd
2 · Reply
Wisenheimer
Wisenheimer Sep. 16 at 5:36 AM
$NMTC new biz dev guy already sold shares at $2
1 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 14 at 5:54 PM
$NMTC StereoCED™ represents an important extension of our core electrode technology into precision intracranial drug delivery. Following three successful large-animal procedures, development of devices for animal use was completed ahead of schedule, allowing sales to begin earlier than anticipated. We expect to recognize the related revenue from this research program during fiscal Q4 2026. Development of devices for human investigational use also remains on track as we continue advancing toward the planned use of StereoCED™ in FDA approved investigational studies. $CLPT $GMED
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 11 at 6:05 PM
$NMTC Our fiscal Q3 results demonstrated progress not only in product revenue, but also in the underlying economics of our commercial business. Product gross profit increased 29% year over year to $1.2 million, while product gross margin reached a record 59.9%, compared with 53.9% during the same period last year. The improvement reflected a more favorable product mix, while higher OneRF® product sales were the primary driver of revenue growth. Together with our ISO 13485 certification, these results strengthen the foundation supporting continued product adoption and our plans to selectively pursue international commercial opportunities. $ABT $MDT $GMED
0 · Reply
IncognitoBull
IncognitoBull Sep. 11 at 12:06 PM
0 · Reply
IncognitoBull
IncognitoBull Sep. 11 at 12:05 PM
$NMTC Parkinson's, Alzheimers, Mood disorders......all possibilities.
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 9 at 3:45 PM
$NMTC During fiscal Q3, product revenue increased 16% year over year to $2.0 million, while new product orders grew 43% to approximately $2.7 million. Orders exceeded recognized revenue during the quarter, contributing to a $1.7 million backlog as of June 30. As of our Q3 update, we had received approximately $11.2 million in product orders for fiscal 2026. We continue working closely with our manufacturing partners to maximize shipments and convert this demand into recognized revenue as we build on the commercial momentum across our portfolio. $CLPT $MDT
0 · Reply
IncognitoBull
IncognitoBull Sep. 9 at 3:18 PM
0 · Reply
IncognitoBull
IncognitoBull Sep. 8 at 8:48 PM
$NMTC Wambeke added 33,333 shares on 8.27.26 at an avg price of $2.01. Split adjusted: 1M to 166,666 + 33,333 = 199,999 shares now.
0 · Reply
NeuroOne_IR
NeuroOne_IR Sep. 8 at 4:17 PM
At NeuroOne, we are building a medical technology platform focused on expanding the role of minimally invasive solutions across neurological disorders and chronic pain. Our commercial portfolio continues to generate growing demand, while programs such as StereoCED™ and basivertebral nerve ablation are designed to extend our technology into additional applications. Fiscal Q3 reflected progress across both sides of this strategy: strengthening the commercial foundation of our business today while continuing to advance the opportunities that may support our longer-term growth. $NMTC $MDT $ABT
0 · Reply
IncognitoBull
IncognitoBull Sep. 8 at 3:39 PM
$NMTC Wambeke's shares were split adjusted, not sold. He is holding
0 · Reply
Wisenheimer
Wisenheimer Sep. 8 at 2:32 PM
$NMTC wow the new biz dev guy Wambecke had 1m shares now down to 199k that’s not looking good for this
1 · Reply
IncognitoBull
IncognitoBull Sep. 1 at 1:09 AM
0 · Reply
NeuroOne_IR
NeuroOne_IR Aug. 28 at 3:15 PM
$NMTC StereoCED™’s latest preclinical milestone represents more than progress within a single development program. It reflects how we continue to build new therapeutic applications from a core electrode technology platform that already supports four FDA-cleared product families and an established commercial business. As StereoCED™ advances toward human investigational use, we see the program as another application of our core technology, combining targeted drug delivery with electrophysiological recording. Across our broader portfolio, we continue to extend that technology into additional diagnostic and therapeutic applications, with a focus on addressing meaningful unmet needs in neurology and pain management.
0 · Reply